Repeated doses of rhenium-186 nanoliposome for cancer that has spread to the brain lining
Official title: Multiple Dose Intraventricular Administration of Rhenium-186 NanoLiposome for Leptomeningeal Metastases
Status: Recruiting. It is looking for patients now. Talk to your care team about whether it fits you.
The trial team last updated this record on .
The short version
This study tests giving a drug in repeated doses through a tube into the fluid spaces of the brain.
Read our full plain-language summary
What the trial team says
This is an open-label, multicenter, Phase 1 study to determine the safety and efficacy of multiple doses at defined intervals of rhenium (186Re) obisbemeda (rhenium-186 nanoliposome, 186RNL) administered via intraventricular catheter for any primary solid tumor cancer with leptomeningeal metastases to identify an MTD/MFD for a given dose, interval duration, and number of doses.
Key facts
- Registry number
- NCT07098806
- Stage of testing
- Phase 1/Phase 2
- Conditions studied
- Leptomeningeal Metastasis
Where it is running
This trial lists 1 site.
-
Texas
- The Cancer Therapy and Research Center at UTHSCSA (San Antonio)
How to use this
Talk to your care team first. They know your history and can tell you whether this trial is worth your time.
Joining a trial is always your choice. A trial is a test, not a proven treatment. Being in one is not a promise that it will help you.
This page is built from the trial's listing on ClinicalTrials.gov, a service of the U.S. National Library of Medicine. That listing is the authority, and it may have changed since we last read it. We do not run this trial and we cannot enroll you in it.